ESA is the standard of care for CKD patients with anemia, despite being associated with several life-threatening adverse events, such as hypertension, thromboembolism, stroke, myocardial infarction, and mortality, particularly above the target Hb range. Here, GSTM1 is linked to hypertensive disorder.